CLINIGEN GROUP PLC LS-001
CLINIGEN GROUP PLC LS-001
Acción · GB00B89J2419 · A1J440 (XLON)
Resumen Indicadores financieros
Sin cotización
n/a

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
- - - - - - -

Perfil de la empresa para CLINIGEN GROUP PLC LS-001 Acción

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Fondos invertidos

Los siguientes fondos han invertido en: CLINIGEN GROUP PLC LS-001 invertido:

Fondo
iShares MSCI UK Small Cap UCITS ETF GBP (Acc)
Vol. en millones
1.081,40
Porcentaje (%)
0,18 %

Datos de la empresa

Nombre CLINIGEN GROUP PLC LS-001
Empresa Clinigen Group plc
Sitio web https://www.clinigengroup.com
Mercado principal XLON London
WKN A1J440
ISIN GB00B89J2419
Tipo de valor Acción
Sector Healthcare
Industria Medical - Distribution
CEO Mr. Shaun Chilton
País Reino Unido
Moneda GBP
Empleados 1,0 T
Dirección Pitcairn House, Crown Square, First Avenue, DE14 2WW STAFFORDSHIRE
Fecha de OPV 2012-09-25
Dividendos de 'CLINIGEN GROUP PLC LS-001'
Fecha ex-dividendo Dividendo por acción
02.12.2021 5,46 GBX
18.03.2021 2,15 GBX
05.11.2020 5,46 GBX
19.03.2020 2,15 GBX
07.11.2019 4,75 GBX
21.03.2019 1,95 GBX
08.11.2018 3,84 GBX
22.03.2018 1,76 GBX
09.11.2017 3,40 GBX
23.03.2017 1,60 GBX

Símbolos de cotización

Nombre Símbolo
London CLIN.L

Otras acciones

Los inversores que tienen CLINIGEN GROUP PLC LS-001 también tienen las siguientes acciones en su cartera:
FRANKREICH 25/25 ZO
FRANKREICH 25/25 ZO Bono
HSBC BANK PLC NTS LKD UKSED3P 22/11/27
HSBC BANK PLC NTS LKD UKSED3P 22/11/27 Bono
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025